Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Vaso-occlusive Crisis

Interventions

DRUG: Placebo
DRUG: Dalteparin

Sponsor

Duke University

Collaborators

[object Object]